<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychol Med</journal-id><journal-id journal-id-type="publisher-id">IJPsyM</journal-id><journal-title-group><journal-title>Indian Journal of Psychological Medicine</journal-title></journal-title-group><issn pub-type="ppub">0253-7176</issn><issn pub-type="epub">0975-1564</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21716778</article-id><article-id pub-id-type="pmc">3122549</article-id><article-id pub-id-type="publisher-id">IJPsyM-32-104</article-id><article-id pub-id-type="doi">10.4103/0253-7176.78506</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Study of the Effect of Nortriptyline and Fluvoxamine on Psychomotor Functions in Healthy Volunteers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khade</surname><given-names>Ajay</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Bashir</surname><given-names>Mohammed Shakeel Mohamemed</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kale</surname><given-names>A. S.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Turankar</surname><given-names>Avinash</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1">Department of Pharmacology, Rajiv Gandhi Institute of Medical Sciences (RIMS), Adilabad, AP, India</aff><aff id="aff2"><label>1</label>Department of Pharmacology, Govt Medical College, Nagpur, India</aff><aff id="aff3"><label>2</label>Department of Pharmacology, Government Medical College, Mumbai, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Ajay Khade Department of Pharmacology, Rajiv Gandhi Institute of Medical Sciences (RIMS), Adilabad, Andhra Pradesh, India. E-mail: <email xlink:href="ajay_khade2000@yahoo.com">ajay_khade2000@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Dec</season><year>2010</year></pub-date><volume>32</volume><issue>2</issue><fpage>104</fpage><lpage>107</lpage><permissions><copyright-statement>&#x000a9; Indian Journal of Psychological Medicine</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Today, many antidepressants are available, but they often cause adverse effects, particularly psychomotor and cognitive. It leads to patient maladjustment and may impair psychomotor performance. Fluvoxamine is a newer antidepressant and hence the present study was planned to investigate its effect on psychomotor functions and compare with nortriptyline and record their adverse reactions.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>A total of 26 healthy volunteers were included in this double-blind, placebocontrolled, crossover study. Single oral doses of fluvoxamine 50 mg, nortriptyline 50 mg and placebo were administered following a Latin square design. The objective parameters-six digit cancellation test, digit symbol substitution test, critical flicker fusion test, arithmetic ability test, hand steadiness test and subjective parameters such as visual analogue scale 1, 2, 3 were tested at 0, 2 and 4 h. The side-effects were also investigated.</p></sec><sec id="st3"><title>Results:</title><p>Nortriptyline impaired all subjective and objective psychomotor functions while fluvoxamine did not show any significant effect on objective tests. However, on subjective parameters, there was a significant effect. The side-effects observed were dryness of mouthwith the nortriptyline and nausea and headache with fluvoxamine.</p></sec><sec id="st4"><title>Conclusion:</title><p>Fluvoxamine is a better antidepressant drug in comparison with nortriptyline as it causes a less impairment of psychomotor functions.</p></sec></abstract><kwd-group><kwd><italic>Fluvoxamine</italic></kwd><kwd><italic>nortriptyline</italic></kwd><kwd><italic>psychomotor function</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Mood disorders appear to afflict at least 12% of women and 8% of men[<xref ref-type="bibr" rid="ref1">1</xref>]. Major depression or unipolar depression is the most common psychiatric disorder. Mental illnesses were earlier not well understood. But, these days, with advanced technology, brain receptors have been mapped.</p><p>In 1957, Kuhn reported that imipramine has antidepressant properties. This was followed by other tricyclics such as amitriptyline, nortriptyline, doxepine, etc. and, later on, the selective serotonin reuptake inhibitor, i.e. fluvoxamine, fluoxetine, sertraline, etc.</p><p>However, to date, the mechanism of action of these antidepressant drugs is yet to be precisely known. Today, many antidepressants are available but they often cause adverse effects, particularly psychomotor and cognitive. This leads to patient maladjustment and may impair psychomotor performance, which plays important role in driving and operating complex machinery. Therefore, it is desirable to develop antidepressant drugs with a minimal effect on these functions so that the patient's productivity or social adjustment are not hampered.</p><p>Fluvoxamine is a newer antidepressant and hence the present study was planned to investigate its effect on psychomotor functions and compare with nortriptyline and record their adverse reactions.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>A total of 26 healthy volunteers, 20 males and six females, of age group -30 years with informed consent were included in this double-blind, placebocontrolled, crossover study. Subjects who were dependent on alcohol, tobacco or other drugs were excluded. A single oral dose of fluvoxamine 50 mg, nortriptyline 50 mg and placebo was administered following a Latin square design. The parameters were tested at 0, 2 and 4 h. Before the study volunteers received training till a performance plateau was reached.</p><sec id="sec2-1"><title>Tests for psychomotor functions: A sensory component</title><sec id="sec3-1"><title>Test for perception</title><p>Six-digit cancellation test (6DCT):[<xref ref-type="bibr" rid="ref2">2</xref>] Volunteers were required to cancel as many target digits as possible in a sheet consisting of 1,200 randomized digits in 3 min.</p></sec><sec id="sec3-2"><title>Test for recognition and recoding</title><p>Digit symbol substitution test (DSST):[<xref ref-type="bibr" rid="ref3">3</xref>] Volunteers were required to insert the corresponding symbol in the space above each digit in a sheet consisting of 200 randomized digits in 2 min.</p></sec><sec id="sec3-3"><title>Test for central integration</title><p>Critical flicker fusion test (CFFT):[<xref ref-type="bibr" rid="ref4">4</xref>] It is a reliable psychometric test as there is no learning curve effect.[<xref ref-type="bibr" rid="ref5">5</xref>] The apparatus consists of a viewing tube at the end of which a red circle of light flickers at the rate of 550 cycles/s. The Critical Fusion Frequency was determined by increasing the frequency from 5 Hz till a steady light source was seen and the Critical Flicker Frequency by decreasing the frequency from 50 Hz till flickering was seen.</p></sec><sec id="sec3-4"><title>Test for central processing</title><p>Arithmetic ability test (AA):[<xref ref-type="bibr" rid="ref6">6</xref>] The subjects had to solve simple mathematical problems, i.e. addition, subtraction, multiplication and division (five of each) within 2 min.</p></sec></sec><sec id="sec2-2"><title>Motor component</title><sec id="sec3-5"><title>Test for steadiness[<xref ref-type="bibr" rid="ref7">7</xref>]</title><p>This was tested by steadiness tester, which consists of holes of different size sand subjects had to insert stylus into the hole without touching its sides.</p></sec></sec><sec id="sec2-4"><title>Subjective component</title><sec id="sec3-6"><title>Visual analogue scale (VAS)[<xref ref-type="bibr" rid="ref8">8</xref>]</title><p>The volunteers were asked to indicate the state of their current feeling by marking on a 100 mm horizontal line. The opposite mood-related adjectives at each end were as follows:</p><p>
<list list-type="order"><list-item><p>Wide awake - extreme sleepy</p></list-item><list-item><p>Alert - dull</p></list-item><list-item><p>Active - tired</p></list-item></list>
</p></sec><sec id="sec3-7"><title>Side-effects</title><p>Volunteers marked their subjectively felt side effects on a sheet.</p></sec><sec id="sec3-8"><title>Statistical analysis of data</title><p>The sample size of 26 was calculated by the institutional statistician. The tests used were ANOVA followed by <italic>post-hoc</italic> Newman-Keuls multiple comparison test.</p></sec></sec></sec><sec sec-type="results|discussion" id="sec1-3"><title>RESULTS AND DISCUSSION</title><p>In the study, nortriptyline 50 mg dose decreased the substitution of symbols score on DSST and the cancellation of digits score on 6DCT [<xref ref-type="table" rid="T1">Table 1</xref>]. It reduced the CFFT threshold and AA score suggestive of impairment of central integrative capacity and central processing ability respectively [<xref ref-type="table" rid="T1">Table 1</xref>] It increased errors in the hand steadiness test, suggestive of motor impairment [<xref ref-type="table" rid="T2">Table 2</xref>]. These findings of nortriptyline on objective tests are also reflected in the subjective assessment of VAS-1, VAS-2 and VAS-3 with a significant shift of the scale toward drowsiness, tiredness and dullness [<xref ref-type="table" rid="T2">Table 2</xref>]. Nortriptyline when compared with fluvoxamine and placebo had shown significant impairment on objective [<xref ref-type="table" rid="T3">Table 3</xref>] and subjective tests at 4 h [<xref ref-type="table" rid="T4">Table 4</xref>]. Thus, in the present study nortriptyline at the dose of 50 mg significantly affected the psychomotor functions. Tricyclics like nortriptyline cause adverse effects of drowsiness and psychomotor impairment due to their antihistaminic, antimuscarinic and &#x00391;<sub>1</sub>-antagonist action.[<xref ref-type="bibr" rid="ref9">9</xref>] . The findings are in arrangement with studies of Ogura, <italic>et al</italic>.,[<xref ref-type="bibr" rid="ref10">10</xref>] Bye <italic>et al</italic>.[<xref ref-type="bibr" rid="ref11">11</xref>] and Seppala, <italic>et al</italic>.[<xref ref-type="bibr" rid="ref12">12</xref>]</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Effects of fluvoxamine and nortriptyline at 0, 2 and 4 h</p></caption><graphic xlink:href="IJPsyM-32-104-g001"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Effects of fluvoxamine and nortriptyline at 0, 2 and 4 h</p></caption><graphic xlink:href="IJPsyM-32-104-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Interdrug comparison of mean difference at 2 and 4 h</p></caption><graphic xlink:href="IJPsyM-32-104-g003"/></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Interdrug comparison of mean difference at 2 and 4 h</p></caption><graphic xlink:href="IJPsyM-32-104-g004"/></table-wrap><p>It is seen from the studies of Curran and Lader[<xref ref-type="bibr" rid="ref13">13</xref>] Fairweather, <italic>et al</italic>.[<xref ref-type="bibr" rid="ref14">14</xref>] Fleishaker and Hulst[<xref ref-type="bibr" rid="ref15">15</xref>] that fluvoxamine 50 mg had no significant effect on objective tests except the study of van Harten[<xref ref-type="bibr" rid="ref16">16</xref>] in which performance was impaired.</p><p>In our study, fluvoxamine in the dose of 50 mg did not show any significant effect on objective tests such as 6DCT, DSST, CFFT, AA test [<xref ref-type="table" rid="T1">Table 1</xref>] and hand steadiness test [<xref ref-type="table" rid="T2">Table 2</xref>]. However, on subjective parameters such as VAS-1, VAS-2 and VAS-3, there was a significant effect indicating a shift of the scale toward drowsiness, tiredness and dullness [<xref ref-type="table" rid="T2">Table 2</xref>]. Also, nortriptyline in comparison with fluvoxamine impaired psychometric tests significantly [Tables <xref ref-type="table" rid="T3">3</xref> and <xref ref-type="table" rid="T4">4</xref>].</p><p>In a recent study of the receptor binding of a wide range of antidepressants in human post-mortem brain, fluvoxamine was among the least-potent compounds at &#x003b1;<sub>1</sub>, &#x003b1;<sub>2</sub>, H<sub>1</sub> and muscarinic receptor sites. This may account for its lack of sedation and consequently lack of impairment of psychomotor function.[<xref ref-type="bibr" rid="ref17">17</xref>] Thus, the findings of effect of fluvoxamine on various psychometric tests in our study substantiate those of the other workers. Further, there is limitation of analogue system as words may fail to describe the exactness of the subjective experience.[<xref ref-type="bibr" rid="ref8">8</xref>]</p><p>The volunteers complained dryness of mouth with nortriptyline due to anticholinergic action and nausea headache with fluvoxamine [<xref ref-type="table" rid="T5">Table 5</xref>]. The cause for nausea, vomiting with fluvoxamine is increased synaptic availability of serotonin which stimulates 5HT<sub>3</sub> receptors. These side-effects are expected and also reported by others.[<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref17">17</xref>]</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Side-effects reported by the volunteers</p></caption><graphic xlink:href="IJPsyM-32-104-g005"/></table-wrap></sec><sec sec-type="conclusion" id="sec1-4"><title>CONCLUSION</title><p>Nortriptyline significantly depresses the objective and subjective psychometric performance in comparison with placebo and fluvoxamine. There was no evidence of impairment of psychometric tests by fluvoxamine in our study. However, it has impaired the subjective test. Dryness of mouth is the reported adverse effect of nortriptyline, whereas nausea and headache are the adverse effects of fluvoxamine. Hence, fluvoxamine can be a better alternative to nortriptyline as it causes minimal psychomotor impairment.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Akiskal</surname><given-names>HS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Kaplan</surname><given-names>NI</given-names></name><name><surname>Sadock</surname><given-names>BJ</given-names></name></person-group><article-title>Mood disorders: Introduction and overview</article-title><source>Comprehensive text book of psychiatry</source><year>1995</year><volume>1</volume><edition>6th ed</edition><publisher-loc>Baltimore</publisher-loc><publisher-name>Williams and Wilkins Co</publisher-name><fpage>1067</fpage><lpage>79</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>BM</given-names></name></person-group><article-title>Pencil and paper tests &#x02013; sensitivity to psychotropic drugs</article-title><source>Br J Clin Pharmacol</source><year>1984</year><volume>18</volume><fpage>15S</fpage><lpage>20S</lpage><pub-id pub-id-type="pmid">6151847</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><article-title>Manual on Clinical Pharmacology</article-title><source>Workshop on clinical pharmacology, Chandigarh: Postgrad Inst Med Ed Res (PGIMER)</source><year>2000</year></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>P</given-names></name></person-group><article-title>Critical flicker frequency and centrally acting drugs</article-title><source>Br J Ophthalmol</source><year>1968</year><volume>52</volume><fpage>245</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">4384626</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>C</given-names></name><name><surname>Kerr</surname><given-names>JS</given-names></name><name><surname>Hindmarch</surname><given-names>I</given-names></name></person-group><article-title>The effects of practice on choice reaction time and critical flicker fusion threshold</article-title><source>Hum Psychopharmacol</source><year>1997</year><volume>12</volume><fpage>65</fpage><lpage>70</lpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worlikar</surname><given-names>P</given-names></name><name><surname>Shaligram</surname><given-names>SV</given-names></name><name><surname>Saraf</surname><given-names>AP</given-names></name></person-group><article-title>Effect of multiple doses of diazepam and promethazine on psychomotor performance of human volunteers</article-title><source>Indian J Pharmacol</source><year>1985</year><volume>17</volume><fpage>30</fpage><lpage>3</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>GS</given-names></name></person-group><article-title>Manual Pharmatech</article-title><source>Techniques in Pharmacology</source><year>1996</year><publisher-loc>Mumbai</publisher-loc><publisher-name>Med Coll and KEM Hosp</publisher-name></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aitken</surname><given-names>RC</given-names></name></person-group><article-title>Measurement of feelings using visual analogue scales</article-title><source>Proc R Soc Med</source><year>1969</year><volume>62</volume><fpage>989</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">4899510</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM</given-names></name></person-group><article-title>Depression</article-title><source>Essential psychopharmacology-neuroscientific basis and practical applications</source><year>1998</year><publisher-loc>New Delhi</publisher-loc><publisher-name>Cambridge University Press</publisher-name><fpage>99</fpage><lpage>130</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogura</surname><given-names>C</given-names></name><name><surname>Kishimoto</surname><given-names>A</given-names></name><name><surname>Mizukawa</surname><given-names>R</given-names></name><name><surname>Matsubayashi</surname><given-names>M</given-names></name><name><surname>Omura</surname><given-names>F</given-names></name><name><surname>Kunimoto</surname><given-names>N</given-names></name></person-group><article-title>Comparative study of the effects of 9 antideprssants on several physiological parameters in healthy volunteers</article-title><source>Neuropsychobiology</source><year>1987</year><volume>17</volume><fpage>139</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">3683803</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bye</surname><given-names>C</given-names></name><name><surname>Clubely</surname><given-names>M</given-names></name><name><surname>Peck</surname><given-names>AW</given-names></name></person-group><article-title>Drowsiness, impaired performance and tricyclic antidepressant drugs</article-title><source>Br J Clin Pharmacol</source><year>1978</year><volume>6</volume><fpage>155</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">678393</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seppala</surname><given-names>T</given-names></name><name><surname>Linnolia</surname><given-names>M</given-names></name><name><surname>Elonen</surname><given-names>E</given-names></name><name><surname>Mattila</surname><given-names>MJ</given-names></name><name><surname>Maki</surname><given-names>M</given-names></name></person-group><article-title>Effect of tricyclic antidepressants and alcohol on psychomotor skills related to driving</article-title><source>Clin Pharmacol Ther</source><year>1975</year><volume>17</volume><fpage>515</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">1092511</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curran</surname><given-names>HV</given-names></name><name><surname>Lader</surname><given-names>M</given-names></name></person-group><article-title>The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects</article-title><source>Eur J Clin Pharmacol</source><year>1986</year><volume>29</volume><fpage>601</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3082644</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairweather</surname><given-names>DB</given-names></name><name><surname>Ashford</surname><given-names>J</given-names></name><name><surname>Hindmarch</surname><given-names>I</given-names></name></person-group><article-title>Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers</article-title><source>Pharmacol Biochem Behav</source><year>1996</year><volume>53</volume><fpage>265</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8808130</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleishaker</surname><given-names>JC</given-names></name><name><surname>Hulst</surname><given-names>LK</given-names></name></person-group><article-title>A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine</article-title><source>Eur J Clin Pharmacol</source><year>1994</year><volume>46</volume><fpage>35</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8005185</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Harten</surname><given-names>J</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Raghoebar</surname><given-names>M</given-names></name><name><surname>Holland</surname><given-names>RL</given-names></name><name><surname>Wesnes</surname><given-names>K</given-names></name><name><surname>Cournot</surname><given-names>A</given-names></name></person-group><article-title>Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function</article-title><source>Clin Pharmacol Ther</source><year>1992</year><volume>52</volume><fpage>427</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">1424416</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benfield</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name></person-group><article-title>Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness</article-title><source>Drugs</source><year>1986</year><volume>32</volume><fpage>313</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">3096686</pub-id></element-citation></ref></ref-list></back></article>